Medtronic FX & Other Adjustments increased by 176.9% to $269.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 171.7%, from $99.00M to $269.00M.
Positive values indicate a favorable currency impact, while negative values indicate a drag on comprehensive income due to currency depreciation.
Represents the gains or losses resulting from the translation of financial statements of foreign subsidiaries into the r...
Standard for multinational corporations with significant international operations and exposure to multiple currencies.
other_goodwill_foreign_currency_translation_gain_loss| Q1 '22 | Q2 '22 | Q1 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | -$268.00M | -$936.00M | -$640.00M | $17.00M | $159.00M | -$487.00M | $99.00M | -$350.00M | $269.00M |
| QoQ Change | — | -249.3% | +31.6% | +102.7% | +835.3% | -406.3% | +120.3% | -453.5% | +176.9% |
| YoY Change | — | — | -138.8% | +102.7% | — | — | +482.4% | +28.1% | +171.7% |
| Segment | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical Surgical | -$204.00M | $77.00M | $70.00M | -$351.00M | $725.00M | $203.00M | — | $54.00M |
| Neuroscience | -$30.00M | $10.00M | $14.00M | -$58.00M | $106.00M | $38.00M | — | $19.00M |
| Cardiovascular | -$20.00M | $11.00M | — | -$42.00M | $88.00M | $28.00M | — | $9.00M |
| Diabetes | $0.00 | $0.00 | $0.00 | $0.00 | $1.00M | $0.00 | $0.00 | $0.00 |
| Total | — | $99.00M | — | -$350.00M | — | $269.00M | — | — |